Eris Lifesciences is planning to raise funds by issuance of Non-Convertible Securities, through permissible modes under applicable law and subject to such regulatory/ statutory approvals, as may be required. The meeting of Board of Directors of the company is scheduled to be held on May 21, 2024, to consider and approve the same.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
